$25.41
-0.13-0.51%
À la fermeture: -
$25.40
-0.01-0.04%
Après les heures de négociation: Nov 14, 7:58 PM EDT
Comments
Loading...
Orientation et prévision
Teva Pharmaceutical Indus publie des prévisions sur le BPA et les revenus futurs, donnant aux investisseurs un aperçu du montant que la société s'attend à gagner au cours des prochaines périodes.
Get Alert | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
11/05/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.55 | $2.65 | $2.53 | $16.80B | $17.00B | $16.86B | |
07/30/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.50 | $2.60 | $2.50 | $16.80B | $17.20B | $16.97B | |
05/07/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.45 | $2.65 | $2.56 | $16.80B | $17.20B | $17.24B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.54 | $16.80B | $17.40B | $17.14B | |
03/27/2025 | TEVA | Teva Pharmaceutical Indus | Q1 | 2025 | $0.52 | $0.52 | $0.48 | $3.99B | $3.99B | $3.98B | |
01/29/2025 | TEVA | Teva Pharmaceutical Indus | FY | 2025 | $2.35 | $2.65 | $2.78 | $16.80B | $17.40B | $17.09B | |
11/06/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.40 | $2.50 | $2.45 | $16.10B | $16.50B | $16.26B | |
07/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.30 | $2.50 | $2.34 | $16.00B | $16.40B | $16.01B | |
05/08/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.41 | $15.70B | $16.30B | $15.86B | |
01/31/2024 | TEVA | Teva Pharmaceutical Indus | FY | 2024 | $2.20 | $2.50 | $2.42 | $15.70B | $16.30B | $15.57B | |
11/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.28 | $15.10B | $15.50B | $15.14B | |
08/02/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.27 | $15.00B | $15.40B | $15.02B | |
05/10/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.40 | $14.80B | $15.40B | $15.06B | |
02/08/2023 | TEVA | Teva Pharmaceutical Indus | FY | 2023 | $2.25 | $2.55 | $2.52 | $14.80B | $15.40B | $15.23B | |
11/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.50 | $14.80B | $15.40B | $15.46B | |
07/26/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | — | $15.00B | $15.60B | $15.67B | |
05/03/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.51 | $15.40B | $16.00B | $15.97B | |
02/09/2022 | TEVA | Teva Pharmaceutical Indus | FY | 2022 | $2.40 | $2.60 | $2.64 | $15.60B | $16.20B | $16.32B |
FAQ
Quelles sont les dernières directives pour Teva Pharmaceutical Indus (TEVA) ?
Les dernières prévisions pour Teva Pharmaceutical Indus (TEVA) ont été communiquées le novembre 5, 2025 pour l'année complète 2025. L'entreprise a fourni des prévisions de bénéfice par action dans une fourchette de $2.55 à $2.65, par rapport à un BPA estimé de $2.53. De plus, Teva Pharmaceutical Indus a prévu un chiffre d'affaires entre $16.80B et $17.00B pour le trimestre.
Parcourir guidance et prévisions sur toutes les actions.